Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

Investigational New Drugs

Volumn 25, Issue 3, 2007, Pages 253-258

  Yana, Takashi ^l   Negoro, Shunichi ^b   Takada, Minoru ^a   Yokota, Soichiro ^c   Takada, Yoshiki ^d   Sugiura, Takahiko ^e   Yamamoto, Hidehiko ^f   Sawa, Toshiyuki ^g   Kawahara, Masaaki ^h   Katakami, Nobuyuki ⁱ   Ariyoshi, Yutaka ^j   Fukuoka, Masahiro ^k  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c National Hospital Organization   (Japan)

^d HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f ASO IIZUKA HOSPITAL   (Japan)

^g Gifu Municipal Hospital   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

ⁱ KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^j AICHI PREFECTURAL UNIVERSITY   (Japan)

^k KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l OTEMAE HOSPITAL   (Japan)

more..

Author keywords

Amrubicin; Anthracycline; Phase II study; Previously untreated patients; Small cell lung cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMRUBICIN; ASPARTATE AMINOTRANSFERASE; CISPLATIN; ETOPOSIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SALVAGE CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; FEVER; HEADACHE; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NITROGEN URINE LEVEL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RASH; RHINORRHEA; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR REGRESSION;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 34248670669     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9012-9     Document Type: Article

References (24)

1. Murren J, Glatstein E, Pass H (2001) Small cell lung cancer. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott Williams and Wilkins, Philadelphia, pp 983-1018
2. Aisner J (1996) Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. J Clin Oncol 14:658-665
3. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N, for the Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91
4. Aisner J, Alberto P, Bitran J, Comis R, Daniels J, Hansen H, Ikegami H, Smyth J (1983) Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 67:37-43
5. Ishizumi K, Ohashi N, Tanno N (1987) Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem 52:4477-4485
6. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M (1989) Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 80:69-76
7. Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M (1989) Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res 80:77-82
8. Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 15:219-225
9. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T (1998) Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 16:121-128
10. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89:1067-1073
11. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 89:1055-1060
12. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T (1998) A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89:1229-1238
13. Negoro S, Fukuoka M, Nakamura S, Ikegami H, Sugiura T, Ariyoshi Y, Takada M, Yana T, Ogawa M (1995) Phase I-II study of amrubicin (SM-5887), a novel 9-aminoanthracycline, by iv administration for 3 consecutive days in patients with advanced non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 14:361
14. Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28:101-130
15. World Health Organization (1979) Handbook for reporting results of cancer treatment (WHO Offst Publication No. 48). World Health Organization, Geneva, Switzerland
16. Kaplan WH, Meier P (1952) Nonparametric estimation from incomplete observations. J Am Atat Assoc 53:583-612
17. Grant SC, Gralla RJ, Kris MG, Orazem J, Kitsis EA (1992) Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol 10:484-498
18. Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, Motomiya M, Kurita Y, Hasegawa K, Kuriyama T, Nishiwaki Y, Ogawa M, Nakao I, Saijo N, Obo K, Furue H, Ariyoshi Y, Shimokata K, Furuse K, Nakajima S, Irie K, Kimura I, Ogura T, Fujii M, Hara N, Hara Y, Nakano N, Araki J, Miyata Y, Taguchi T (1991) A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Jpn J Cancer Chemother 18:1013-1019
19. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229
20. Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D (1996) Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14:2345-2352
21. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435
22. Kirschling R, Jung S, Jett J (1994) A phase II study of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 13:326
23. Hesketh P, Crowley J, Burris HA 3rd, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF Jr, Livingston RB, Gandara DR (1999) Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am 5:237-241
24. Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D (1994) Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5:283-285